Myositis;Myositiden

Nervenheilkunde

Volumn 30, Issue 10, 2011, Pages 776-786

  Jordan, Berit ^a   Hanisch, F ^a   Zierz, S ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Antibodies; Antisynthetase syndrome; Myositis; Necrotising myopathy; Overlap syndrome

Indexed keywords

ANTIBODY;

DERMATOMYOSITIS; HEART DISEASE; HUMAN; IMMUNE MEDIATED NECROTIZING MYOPATHY; LUNG DISEASE; MYOPATHY; MYOSITIS; ORBITAL MYOSITIS; REVIEW; RISK FACTOR; SEROLOGY;

EID: 80054053312     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1628425     Document Type: Review

References (63)

1. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292(7): 344-7.
2. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292(8): 403-7.
3. Hengstman GJ, van Engelen BG, van Venrooij WJ. Myositis specific autoantibodies: changing insights in pathophysiology and clinical associations. Curr Opin Rheumatol 2004; 16(6): 692-9. (Pubitemid 39425542)
4. Mammen AL. Dermatomyositis and polymyositis: Clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010; 1184: 134-53.
5. Dalakas MC. Inflammatory muscle diseases: a critical review on pathogenesis and therapies. Curr Opin Pharmacol 2010; 10(3): 346-52.
6. Dalakas M, Karpati G. In: Karpati G et al. Disorders of voluntary muscle. 8th ed. Cambridge: University Press 2010.
7. Euwer RL, Sontheimer RD. Amyopathic dermatomyositis (dermatomyositis sine myositis). Presentation of six new cases and review of the literature. J Am Acad Dermatol 1991; 24(6 Pt 1): 959-66.
8. Lam WW et al. MR imaging in amyopathic dermatomyositis. Acta Radiol 1999; 40(1): 69-72. (Pubitemid 129551572)
9. Gerami P et al. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis sine myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol 2006; 54(4): 597-613.
10. Azuma K et al. Incidence and predictive factors for malignancies in 136 Japanese patients with dermatomyositis, polymyositis and clinically amyopathic dermatomyositis. Mod Rheumatol 2010; 21(2): 178-83.
11. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984; 16(2): 193-208.
12. van der Meulen MF et al. Polymyositis: an overdiagnosed entity. Neurology 2003; 61(3): 316-21.
13. Gallardo E, de Andres I, Illa I. Cathepsins are upregulated by IFN-gamma/STAT1 in human muscle culture: a possible active factor in dermatomyositis. J Neuropathol Exp Neurol 2001; 60(9): 847-55. (Pubitemid 32880592)
14. Troyanov Y et al. Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine (Baltimore). 2005; 84(4): 231-49. (Pubitemid 41026298)
15. Nishikai M, Reichlin M. Heterogeneity of precipitating antibodies in polymyositis and dermatomyositis. Characterization of the Jo-1 antibody system. Arthritis Rheum 1980; 23(8): 881-8. (Pubitemid 10040117)
16. Targoff IN. Autoantibodies and their significance in myositis. Curr Rheumatol Rep 2008; 10(4): 333-40.
17. Stone KB et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum 2007; 56(9): 3125-31. (Pubitemid 47502760)
18. Yoshifuji H et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity 2006; 39(3): 233-41. (Pubitemid 43879036)
19. Hengstman GJ et al. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis 2006; 65(2): 242-5. (Pubitemid 43132001)
20. Okada S et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum 2003; 48(8): 2285-93.
21. Burd CJ, Kinyamu HK, Miller FW, Archer TK. UV radiation regulates Mi-2 through protein translation and stability. J Biol Chem 2008; 283(50): 34976-82.
22. Reeves WH, Nigam SK, Blobel G. Human autoantibodies reactive with the signal-recognition particle. Proc Natl Acad Sci USA 1986; 83(24): 9507-11. (Pubitemid 17223389)
23. Miller T, Al-Lozi MT, Lopate G, Pestronk A. Myopathy with antibodies to the signal recognition particle: clinical and pathological features. J Neurol Neurosurg Psychiatry 2002; 73(4): 420-8.
24. Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV. Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 2004; 50(1): 209-15. (Pubitemid 38084306)
25. Targoff IN et al. A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum 2006; 54(11): 3682-9. (Pubitemid 44737181)
26. Kaji K et al. Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology (Oxford) 2007; 46(1): 25-8. (Pubitemid 44932779)
27. Gunawardena H et al. Clinical associations of autoantibodies to a p155/140 kDa doublet protein in juvenile dermatomyositis. Rheumatology (Oxford) 2008; 47(3): 324-8. (Pubitemid 351267200)
28. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48(6): 607-12.
29. Labirua A, Lundberg IE. Interstitial lung disease and idiopathic inflammatory myopathies: progress and pitfalls. Curr Opin Rheumatol 2010; 22(6): 633-8.
30. Koenig M, Fritzler MJ, Targoff IN, Troyanov Y, Senecal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther 2007; 9(4): R78.
31. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007; 19(6): 523-9. (Pubitemid 47530870)
32. Vancsa A et al. Myositis-specific and myositis-associated antibodies in overlap myositis in comparison to primary dermatopolymyositis: Relevance for clinical classification: retrospective study of 169 patients. Joint Bone Spine 2010; 77(2): 125-30.
33. Hall S, Hanrahan P. Muscle involvement in mixed connective tissue disease. Rheum Dis Clin North Am 2005; 31(3): 509-17. (Pubitemid 41111552)
34. Rutjes SA et al. Anti-Ro52 antibodies frequently cooccur with anti-Jo-1 antibodies in sera from patients with idiopathic inflammatory myopathy. Clin Exp Immunol 1997; 109(1): 32-40. (Pubitemid 27293880)
35. Vancsa A et al. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009; 29(9): 989-94.
36. Emslie-Smith AM, Engel AG. Necrotizing myopathy with pipestem capillaries, microvascular deposition of the complement membrane attack complex (MAC), and minimal cellular infiltration. Neurology 1991; 41(6): 936-9.
37. Authier FJ, Kondo H, Ghnassia RT, Revuz J, Gherardi RK. Necrotizing myopathy with pipestem capillaries and minimal cellular infiltration: a case associated with cutaneous signs of dermatomyositis. Neurology 1996; 46(5): 1448-51. (Pubitemid 26159312)
38. Dimitri D, Andre C, Roucoules J, Hosseini H, Humbel RL, Authier FJ. Myopathy associated with antisignal recognition peptide antibodies: clinical heterogeneity contrasts with stereotyped histopathology. Muscle Nerve 2007; 35(3): 389-95. (Pubitemid 46364097)
39. Sampson JB et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord 2007; 17(5): 404-8. (Pubitemid 46679235)
40. Lundberg IE. The heart in dermatomyositis and polymyositis. Rheumatology (Oxford) 2006; 45 Suppl 4: iv18-21. (Pubitemid 44446758)
41. Denbow CE, Lie JT, Tancredi RG, Bunch TW. Cardiac involvement in polymyositis: a clinicopathologic study of 20 autopsied patients. Arthritis Rheum 1979; 22(10): 1088-92. (Pubitemid 10161246)
42. Jordan B, Eger K, Zierz S. [Polymyositis associated with thymoma]. Nervenarzt 2009; 80(6): 708-11.
43. Riemekasten G et al. Beware of the heart: the multiple picture of cardiac involvement in myositis. Rheumatology (Oxford) 1999; 38(11): 1153-7. (Pubitemid 29537341)
44. Fathi M et al. Interstitial lung disease in polymyositis and dermatomyositis: longitudinal evaluation by pulmonary function and radiology. Arthritis Rheum 2008; 59(5): 677-85. (Pubitemid 351679543)
45. Sato S et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005; 52(5): 1571-6. (Pubitemid 40663949)
46. Nakashima R et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 2010; 49(3): 433-40.
47. Mukae H et al. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis. Chest 2009; 136(5): 1341-7.
48. Chinoy H et al. In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtype. Arthritis Res Ther 2006; 8(1): R13.
49. Dalakas MC. Immunotherapy of myositis: issues, concerns and future prospects. Nat Rev Rheumatol 2010; 6(3): 129-37.
50. Kim J, Kim YW, Lee SM, Kim YS, Kim YT, Song YW. Successful lung transplantation in a patient with dermatomyositis and acute form of interstitial pneumonitis. Clin Exp Rheumatol 2009; 27(1): 168-9.
51. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134(12): 1087-95.
52. Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part I. Clin Exp Dermatol 2009; 34(4): 451-5.
53. Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis-like skin disease:retrospective review of 16 cases with amyopathic dermatomyositis. Clin Rheumatol 2009; 28(8): 979-84.
54. Hill CL et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a populationbased study. Lancet 2001; 357(9250): 96-100. (Pubitemid 32094911)
55. Trallero-Araguas E et al. Cancer-associated myositis and anti-p155 autoantibody in a series of 85 patients with idiopathic inflammatory myopathy. Medicine (Baltimore) 2010; 89(1): 47-52.
56. Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol 2009; 34(5): 561-5.
57. Selva-O'Callaghan A et al. Conventional cancer screening versus PET/CT in dermatomyositis/polymyositis. Am J Med 2010; 123(6): 558-62.
58. Ponyi A et al. Cancer-associated myositis: clinical features and prognostic signs. Ann N Y Acad Sci 2005; 1051: 64-71. (Pubitemid 41362733)
59. Schoser BG. Ocular myositis: diagnostic assessment, differential diagnoses, and therapy of a rare muscle disease - five new cases and review. Clin Ophthalmol 2007; 1(1): 37-42.
60. Bau V, Sievert M, Roggenkamper P, Zierz S. Cyclic vertical deviation after ocular myositis and treatment by recession of the inferior rectus muscle. Graefes Arch Clin Exp Ophthalmol 2005; 243(10): 1062-5. (Pubitemid 41631049)
61. Krasnianski M, Sievert M, Bau V, Zierz S. External ophthalmoplegia due to ocular myositis in a patient with ophthalmic herpes zoster. Neuromuscul Disord 2004; 14(7): 438-41. (Pubitemid 38798262)
62. Jacobs D, Galetta S. Diagnosis and management of orbital pseudotumor. Curr Opin Ophthalmol 2002; 13(6): 347-51. (Pubitemid 35397641)
63. Dalakas MC. Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future. Neuromuscul Disord 2006; 16(4): 223-36.